(Q46463625)

22 December 2017

title

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study (English)

1 reference

22 December 2017

0 references

1 reference

1 reference

11

Jedd D Wolchok

1 reference

22 December 2017

Katherine S Panageas

4

object named as

Katherine S Panageas

1 reference

22 December 2017

author name string

Wen-Jen Hwu

1

1 reference

22 December 2017

Eric Lis

2

1 reference

22 December 2017

Jennifer H Menell

3

1 reference

22 December 2017

Lynne A Lamb

5

1 reference

22 December 2017

Janene Merrell

6

1 reference

22 December 2017

Linda J Williams

7

1 reference

22 December 2017

Susan E Krown

8

1 reference

22 December 2017

Paul B Chapman

9

1 reference

22 December 2017

Philip O Livingston

10

1 reference

22 December 2017

Alan N Houghton

12

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

22 December 2017

published in

Cancer

1 reference

22 December 2017

volume

103

1 reference

22 December 2017

issue

12

1 reference

22 December 2017

page(s)

2590-2597

1 reference

22 December 2017

Cerebral metastases of cutaneous melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Thalidomide: a new anticancer drug?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Treatment of metastatic melanoma in the brain with temozolomide and thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Determinants of outcome in melanoma patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Treatment of brain metastases from melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21081

7 January 2021

Identifiers

DOI

10.1002/CNCR.21081

1 reference

22 December 2017

PubMed ID

15861414

1 reference

22 December 2017